Successful completion of this activity requires that participants: register for the activity; review the required CE information included in this handout; attend the program; and complete the evaluation form.

Faculty
Jeffrey Cohen, MD, has worked at Cleveland Clinic's Mellen Center for Multiple Sclerosis Treatment and Research since 1994 and became Director in 2014. Dr. Cohen has a large clinical practice devoted primarily to the care of patients with multiple sclerosis and related disorders. In addition, he is Director of the Experimental Therapeutics Program and has been involved in various capacities in a large number of clinical trials developing new therapies for multiple sclerosis. As Director of the Clinical Neuroimmunology Fellowship, he has trained over 30 fellows, many of whom have gone on to be prominent in the field. Dr. Cohen has served on a large number of grant review committees, advisory groups and national and International task forces. He has over 180 publications concerning immunologic, clinical and research aspects of multiple sclerosis and is frequently invited to speak on these topics.

Target Audience
This activity has been designed to meet the educational needs of physicians, advanced practice clinicians, nursing professionals and other members of the healthcare team who manage patients with MS.

Learning Objectives
Upon completion of this activity participants should be able to:
- Identify the various cell-based strategies under study as potential therapy for MS
- Discuss the potential benefits, risks, and methodological uncertainties with stem cell transplantation

Disclosure of Financial Relationships
In accordance with the ACCME Standards for Commercial Support, CMSC, NMSS, and VAMSCoE require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. CMSC, NMSS, and VAMSCoE resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC, NMSS, and VAMSCoE seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC, NMSS, and VAMSCoE are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
Faculty Disclosures
Jeffrey Cohen, MD discloses the following relevant financial relationships:
Consultant: Convelo, Population Council
Speaker Bureau: Mylan
Editor of Multiple Sclerosis Journal

Staff Disclosures
The planners, reviewers, editors, staff, or other members at CMSC, NMSS, and VAMSCoE who control content have declared that they have no relevant financial relationships.

Disclosure of Unlabeled Use
CMSC, NMSS, and VAMSCoE require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Disclaimer
CMSC, NMSS and VAMSCOE present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care.
CMSC, NMSS, and the VAMSCoE assume no liability for the information herein.

Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC), the National Multiple Sclerosis Society (NMSS), and the VA MS Centers of Excellence (VAMSCoE). CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

| PHYSICIANS | The Consortium of Multiple Sclerosis Centers designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
| NURSES | The Consortium of Multiple Sclerosis Centers designates this activity for 1 contact hour of continuing education for nurses. |
| PAS | The Consortium of Multiple Sclerosis Centers (CMSC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation. |

All other healthcare professionals completing this program will be issued a certificate of participation.

If you have any questions about this activity, please contact the National MS Society at healthprof_info@nmss.org